KR20210119457A - 브루톤 티로신 키나제 억제제를 이용한 류마티스 관절염, 만성 자발성 두드러기 및 전신 홍반 루푸스의 치료 방법 - Google Patents

브루톤 티로신 키나제 억제제를 이용한 류마티스 관절염, 만성 자발성 두드러기 및 전신 홍반 루푸스의 치료 방법 Download PDF

Info

Publication number
KR20210119457A
KR20210119457A KR1020217026474A KR20217026474A KR20210119457A KR 20210119457 A KR20210119457 A KR 20210119457A KR 1020217026474 A KR1020217026474 A KR 1020217026474A KR 20217026474 A KR20217026474 A KR 20217026474A KR 20210119457 A KR20210119457 A KR 20210119457A
Authority
KR
South Korea
Prior art keywords
treatment
patient
fenebrutinib
dose
weeks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020217026474A
Other languages
English (en)
Korean (ko)
Inventor
타미코 카츠모토
레슬리 친
엘리사 모리모토
데이비드 제임스 하돈
Original Assignee
에프. 호프만-라 로슈 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에프. 호프만-라 로슈 아게 filed Critical 에프. 호프만-라 로슈 아게
Publication of KR20210119457A publication Critical patent/KR20210119457A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020217026474A 2019-01-22 2020-01-21 브루톤 티로신 키나제 억제제를 이용한 류마티스 관절염, 만성 자발성 두드러기 및 전신 홍반 루푸스의 치료 방법 Pending KR20210119457A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962795477P 2019-01-22 2019-01-22
US62/795,477 2019-01-22
US201962913270P 2019-10-10 2019-10-10
US62/913,270 2019-10-10
PCT/US2020/014346 WO2020154252A1 (en) 2019-01-22 2020-01-21 Methods of treating rheumatoid arthritis, chronic spontaneous urticaria, and systemic lupus erythematosis using an inhibitor of bruton's tyrosine kinase

Publications (1)

Publication Number Publication Date
KR20210119457A true KR20210119457A (ko) 2021-10-05

Family

ID=69726724

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217026474A Pending KR20210119457A (ko) 2019-01-22 2020-01-21 브루톤 티로신 키나제 억제제를 이용한 류마티스 관절염, 만성 자발성 두드러기 및 전신 홍반 루푸스의 치료 방법

Country Status (11)

Country Link
US (1) US12544372B2 (https=)
EP (1) EP3914250A1 (https=)
JP (3) JP2022523018A (https=)
KR (1) KR20210119457A (https=)
CN (3) CN113423401A (https=)
AU (2) AU2020213265B2 (https=)
CA (1) CA3125236A1 (https=)
IL (1) IL284779A (https=)
MX (2) MX2021008696A (https=)
TW (1) TW202042815A (https=)
WO (1) WO2020154252A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021249129A1 (en) 2020-04-03 2022-10-20 F. Hoffmann-La Roche Ag Methods of treating relapsing Multiple Sclerosis using an inhibitor of Bruton's tyrosine kinase
WO2024235166A1 (zh) * 2023-05-12 2024-11-21 武汉人福创新药物研发中心有限公司 含有btk抑制剂的组合物及其用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX362591B (es) * 2010-11-05 2019-01-25 Novartis Ag Uso de antagonistas de il-17.
UA111756C2 (uk) 2011-11-03 2016-06-10 Ф. Хоффманн-Ля Рош Аг Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона
EP4049660B1 (en) 2016-02-29 2025-02-19 F. Hoffmann-La Roche AG Dosage form compositions comprising an inhibitor of bruton's tyrosine kinase
JP2020514384A (ja) 2017-03-24 2020-05-21 ジェネンテック， インコーポレイテッド 自己免疫及び炎症性疾患を治療する方法

Also Published As

Publication number Publication date
AU2020213265A1 (en) 2021-07-22
MX2025013950A (es) 2026-03-02
IL284779A (en) 2021-08-31
MX2021008696A (es) 2021-08-19
TW202042815A (zh) 2020-12-01
CN113423401A (zh) 2021-09-21
WO2020154252A1 (en) 2020-07-30
CN118662512A (zh) 2024-09-20
AU2020213265B2 (en) 2025-01-16
AU2025201888A1 (en) 2025-04-03
JP2022523018A (ja) 2022-04-21
CA3125236A1 (en) 2020-07-30
US12544372B2 (en) 2026-02-10
JP2026041743A (ja) 2026-03-10
EP3914250A1 (en) 2021-12-01
US20220047588A1 (en) 2022-02-17
CN118453606A (zh) 2024-08-09
JP2024099575A (ja) 2024-07-25

Similar Documents

Publication Publication Date Title
JP2026041743A (ja) ブルトン型チロシンキナーゼの阻害剤を使用する関節リウマチ、慢性自発性蕁麻疹、および全身性エリテマトーデスの処置方法
Daien et al. Predictive factors of response to biological disease modifying antirheumatic drugs: towards personalized medicine
Genovese et al. LY2439821, a humanized anti–interleukin‐17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I randomized, double‐blind, placebo‐controlled, proof‐of‐concept study
Holdgate et al. Recent advances in primary Sjogren's syndrome
US20160346386A1 (en) Methods for using extracellular adenosine inhibitors and adenosine receptor inhibitors to enhance immune response and inflammation
Rathee et al. Immunosuppressants: A review
KR102766960B1 (ko) 전신성 홍반성 루푸스에서 i형 인터페론 억제
CN118948848A (zh) 用于治疗免疫缺陷病的方法
KR20220163986A (ko) 브루톤 티로신 키나아제의 억제제를 이용한 재발성 다발성 경화증의 치료 방법
Chen et al. Case report: JAKi and TNFi dual therapy is a potential treatment strategy for difficult-to-treat rheumatoid arthritis
Naniwa et al. Adding low dose tacrolimus in rheumatoid arthritis patients with an inadequate response to tumor necrosis factor inhibitor therapies
US20120039867A1 (en) Immune System Function in Conditions Characterized by Elevated Double Strand Breaks
HK40056367A (en) Methods of treating rheumatoid arthritis, chronic spontaneous urticaria, and systemic lupus erythematosis using an inhibitor of bruton’s tyrosine kinase
US20230091561A1 (en) Methods of treating primary progressive multiple sclerosis using an inhibitor of bruton's tyrosine kinase
Mendoza et al. Coronavirus disease 2019 management strategies in solid organ transplant recipients
Kumar et al. FIP1L1-PDGFRA-Positive Chronic Eosinophilic Leukemia: A Low-Burden Disease with Dramatic Response to Imatinib-A Report of 5 Cases from South India/FIP1L1-PDGFRA Pozitif Kronik Eozinofilik Lösemi: Imatinib için Dramatik Yanit ile Bir Düsük Yük Hastaligi-Güney Hindistan'dan 5 Olgu Sunumu
CN114423782A (zh) 不含钙调磷酸酶抑制剂的ctla4-ig+抗il6/il6r用于对实体器官移植受体进行长期免疫抑制的用途
Takeda et al. Recent advances in the diagnosis and treatment of refractory ocular inflammatory diseases: focus on uveitic macular edema, acute retinal necrosis, and vitreoretinal lymphoma
Kwon et al. Transaminase changes in Korean rheumatoid arthritis patients with chronic hepatitis C after biologic therapy
TADA et al. New Therapy in Rheumatoid Arthritis Biological DMARDs and JAK Inhibitors
Ibrahim et al. Advances in Treatment of Juvenile Idiopathic Arthritis
Vionnet Towards personalised immunosuppression minimisation in liver transplantation: From subclinical allograft damage to tolerance
Dona et al. Leflunomide Confers Rapid Recovery from COVID-19 and is Coupled with Temporal Immunologic Changes
Raje et al. EVALUATING PATIENTS WITH RECURRENT FEVER AND ELEVATED IGD
Tian et al. Application of Antirheumatic Drugs During the Epidemic Period of COVID-19

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000